Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2012 Feb 16;11(4):864–872. doi: 10.1158/1535-7163.MCT-11-0813

Figure 1.

Figure 1

A, Binding of GAL-F2, other anti-FGF2 mAbs and negative control mAb mIgG to human FGF2 measured by ELISA; B, Competitive binding ELISA of anti-FGF2 mAbs against biotinylated GAL-F2; C, Binding ELISA of GAL-F2 to human FGF2 (hFGF2) and mouse FGF2 (mFGF2). In C, the curves for control mIgG binding superimpose and cannot be distinguished.